

## Novalung records 50% growth

Date: 03-17-2010 11:35 AM CET

Category: [Health & Medicine](#)

Press release from: [Novalung GmbH](#)

The innovative therapies for lung failure from medical device company Novalung GmbH continue to gain acceptance. Additional financing will allow the Talheim (Germany) based company to accelerate the development of new products.

Novalung GmbH increased sales by 50% in 2009. The positive trend continues through the first months of 2010. The increasing acceptance of the company's innovative therapies for lung failure both in Germany and abroad is driving continuing growth. Manufacturing operations moved into a new, larger clean-room facility in the Heilbronn (Germany) area at the end of 2009.

In order to maintain this growth and to fund further international expansion, the private equity group Zukunftsfonds Heilbronn GmbH & Co.KG („Future Fund of Heilbronn“, zfhf) and the LBank, state bank of Baden-Württemberg, completed an additional financing round for Novalung. The zfhf acted as lead investor for the second time.

Thanks to the additional funding the development and commercialization of new products can be pursued more aggressively. These measures put Novalung in an excellent position to establish itself internationally as the pioneering provider of solutions for lung failure, and to revolutionize the treatment of lung failure with new therapies.

Novalung products allow a paradigm shift from the mechanically ventilated patient in an artificial coma to the awake, mobile patient breathing spontaneously. The innovative technologies to replace mechanical ventilation and eliminate the associated ventilator-induced lung injury continue this approach and provide physicians, nurses and patients with new therapeutic options.

Novalung's vision for the future for the long-term treatment of patients with advanced lung disease is a small, wearable artificial lung that frees patients from respiratory stress, improves their overall condition and thus improves their quality of life.

Novalung – Driver of a paradigm shift

Founded in 2003, the German company Novalung GmbH operates on a highly international level in order to establish new solutions for lung failure. These advanced technologies from Germany and the U.S. were brought into the company and developed further. The goal is to replace the damaging invasive ventilation. The overall objective is to replace damaging invasive mechanical ventilation.

The privately funded Novalung GmbH is a fast growing medical technology company based in the area of Heilbronn/Germany and a subsidiary on the campus of the University of Michigan at Ann Arbor, USA.

Mrs Franziska Preissing

Head of Marketing

Phone: +49 7133 90 11 130

Fax: +49 7133 90 11 230

[franziska.preissing@novalung.com](mailto:franziska.preissing@novalung.com)

Novalung GmbH

Egerten 3

Germany, 74388 Talheim

[www.novalung.com](http://www.novalung.com)

[You can find this press release here](#)